Contribution of prostaglandins to the systemic and renal vascular response to frusemide in normal man.
In eight normotensive male volunteers indomethacin decreased both the peak urine flow rate and total sodium excreted within 1 h of an intravenous dose of frusemide. Resting effective renal plasma flow and glomerular filtration rate were unchanged by indomethacin, but the increase in both parameters after frusemide was inhibited. The early increase in plasma renin activity after frusemide was inhibited by indomethacin. Indomethacin decreased urinary excretion of PGE by 80% and the increase after frusemide was abolished. The urinary excretion of a metabolite of systemic PGI2 was unaltered in the 40-60 min period following frusemide. The early haemodynamic effects of frusemide are likely to be prostaglandin mediated, but there was no evidence of any change in systemic PGI2 synthesis after frusemide.
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D000328:Adult; D016861:Cyclooxygenase Inhibitors; D015232:Dinoprostone; D011464:Epoprostenol / Q000096:biosynthesis / Q000652:urine; D005665:Furosemide / Q000494:pharmacology*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D011453:Prostaglandins / Q000096:biosynthesis*; D011458:Prostaglandins E / Q000096:biosynthesis / Q000652:urine; D012079:Renal Circulation / Q000187:drug effects; D012082:Renal Veins / Q000187:drug effects*; D012083:Renin / Q000097:blood
D016861:Cyclooxygenase Inhibitors; D011453:Prostaglandins; D011458:Prostaglandins E; D015121:6-Ketoprostaglandin F1 alpha; D005665:Furosemide; D011464:Epoprostenol; D012083:Renin; D015232:Dinoprostone; D007213:Indomethacin